Alfred Kibowen
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Alfred Kibowen has a total of 32 co-authors. Here are the top co-authors by number of shared publications:
- Andre Luiz Teles e Silva
Faculdade Israelita de Ciências da Saúde Albert Einstein, Hospital Israelita Albert Einstein, São Paulo, SP, Brazil
1 shared publication - Annabel Sen
Department of Psychiatry, Division of Molecular Psychiatry, Yale University School of Medicine, New Haven, USA
1 shared publication - April Pruitt
Interdepartmental Neuroscience Program, Yale School of Medicine, New Haven, USA
1 shared publication - Charlotte Becker
Division of Molecular Psychiatry, Department of Psychiatry, Yale University School of Medicine, New Haven, USA
1 shared publication - Elizabeth A. Davidson
Child Study Center, Yale University School of Medicine, New Haven, USA
1 shared publication - Ellen J. Hoffman
Child Study Center, Yale School of Medicine
1 shared publication
Latest Publications
- Top Cited PapersOpen Access
- 24 April 2026
- Published by Springer Nature in Nature Neuroscience
- Vol. 29 (5) , 1079-1094
Transcriptomic and phenotypic convergence of neurodevelopmental disorder risk genes in vitro and in vivo
Diverse risk genes have been identified for neurodevelopmental disorders (NDDs), but how these genes converge on similar biological pathways in neurons, and thus give rise to similar phenotypes, is unclear. Here we apply a pooled CRISPR approach to successfully target 23 NDD loss-of-function genes with roles in chromatin biology and examine convergent effects on gene expression across human induced pluripotent stem cell-derived neural progenitor cells, glutamatergic neurons and GABAergic neurons. Points of convergence vary between these cell types, with the greatest number of convergent genes and strongest convergent networks in mature glutamatergic neurons, where they broadly represent synaptic, epigenetic and, unexpectedly, mitochondrial pathways. The most convergent networks were observed between NDD genes with shared biological annotations, clinical associations and co-expression patterns in human post-mortem brain. Drugs that were predicted to reverse convergent transcriptomic signatures and/or arousal and sensory processing behaviors ameliorated behavioral phenotypes in zebrafish NDD gene mutants. These results suggest that convergent effects of NDD risk genes could provide clinically useful insights.
- 24 April 2026
- Published by Springer Nature in Nature Neuroscience
- Vol. 29 (5) , 1079-1094
Top Cited PapersOpen AccessTranscriptomic and phenotypic convergence of neurodevelopmental disorder risk genes in vitro and in vivo
Diverse risk genes have been identified for neurodevelopmental disorders (NDDs), but how these genes converge on similar biological pathways in neurons, and thus give rise to similar phenotypes, is unclear. Here we apply a pooled CRISPR approach to successfully target 23 NDD loss-of-function genes with roles in chromatin biology and examine convergent effects on gene expression across human induced pluripotent stem cell-derived neural progenitor cells, glutamatergic neurons and GABAergic neurons. Points of convergence vary between these cell types, with the greatest number of convergent genes and strongest convergent networks in mature glutamatergic neurons, where they broadly represent synaptic, epigenetic and, unexpectedly, mitochondrial pathways. The most convergent networks were observed between NDD genes with shared biological annotations, clinical associations and co-expression patterns in human post-mortem brain. Drugs that were predicted to reverse convergent transcriptomic signatures and/or arousal and sensory processing behaviors ameliorated behavioral phenotypes in zebrafish NDD gene mutants. These results suggest that convergent effects of NDD risk genes could provide clinically useful insights.